Drug intelligence / Profile preview

Jiaoqishe

Development stage: Unknown
Lead developer: Changsha Tuoyang Medicine Technology
Modality: Small Molecules
Administration: Oral

Overview

Jiaoqishe is a traditional Chinese medicine (TCM) formulation developed by Changsha Tuoyang Pharmaceutical Technology Co., Ltd. for the treatment of knee osteoarthritis. The formulation is a complex mixture of herbal and animal-derived components, traditionally including ingredients such as musk and gelatinous substances, which are intended to provide analgesic and anti-inflammatory benefits. It is designed to alleviate joint pain, reduce swelling, and improve physical function in patients suffering from degenerative joint disease. As of recent clinical records, Jiaoqishe has been evaluated in Phase II clinical trials in China to establish its safety and therapeutic efficacy compared to standard treatments for osteoarthritis.

Brand names: Jiaoqishe
Other names: Jiaoqishe Capsules胶奇麝胶囊

Beyond the preview

Go deeper on Jiaoqishe.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiaoqishe.

Explore the full profile